Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Gastroenterol Hepatol
Autores principales: Meserve, Joseph, Aniwan, Satimai, Koliani-Pace, Jenna L., Shashi, Preeti, Weiss, Aaron, Faleck, David, Winters, Adam, Chablaney, Shreva, Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Hartke, Justin G., Chilukuri, Prianka, Bohm, Matthew, Sagi, Sashidhar Varma, Fischer, Monika, Lukin, Dana, Hudesman, David, Chang, Shannon, Gao, Youran, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/
https://ncbi.nlm.nih.gov/pubmed/30268561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares